355 results on '"Fraser, John D."'
Search Results
52. Status of research and development of vaccines for Streptococcus pyogenes.
53. Therapeutic potential of staphylococcal superantigen-like protein 7 for acute complement activation-mediated diseases
54. Development of Group A streptococcal vaccines: an unmet global health need
55. The complete primary structure of the T -Cell receptor genes from an alloreactive cytotoxic human T-lymphocyte clone
56. A solubilized T-cell receptor from a human leukemia cell line binds to a ligand in the absence of MHC products
57. Cell-surface expression of H-2Db requires N-linked glycans
58. A Human Cytotoxic Lymphocyte Subdividing the DQ1 Antigen
59. A simple solid phase, peptide-based fluorescent assay for the efficient and universal screening of HRV 3C protease inhibitors
60. M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New Zealand
61. Increasing incidence of invasive group A streptococcus disease in New Zealand, 2002–2012: A national population-based study
62. Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop.
63. Vaccination with Streptococcus pyogenes nuclease A stimulates a high antibody response but no protective immunity in a mouse model of infection
64. ChemInform Abstract: Iridium‐Catalyzed C—H Borylation Facilitates a Total Synthesis of the HRV 3C Protease Inhibitor (.+‐.)‐Thysanone.
65. Staphylococcus aureusInfections in New Zealand, 2000–2011
66. Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop
67. An Engineered Non-Toxic Superantigen Increases Cross Presentation of Hepatitis B Virus Nucleocapsids by Human Dendritic Cells
68. Synthesis of the 2-methylene analogue of the HRV 3C protease inhibitor thysanone (2-carbathysanone)
69. [ABI Seminars] A view of the immune system from the eye of a pathogen
70. Incidence, trends and demographics of Staphylococcus aureus infections in Auckland, New Zealand, 2001–2011
71. Synthesis and Biological Evaluation of 7-Deoxy Analogues of the Human Rhinovirus 3C Protease Inhibitor Thysanone
72. Characterization of a Mouse-Adapted Staphylococcus aureus Strain
73. Clinical and Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus in New Zealand: Rapid Emergence of Sequence Type 5 (ST5)-SCCmec-IV as the Dominant Community-Associated MRSA Clone
74. A modified superantigen rescues Ly6G−CD11b+blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE
75. Development of Group A streptococcal vaccines: an unmet global health need.
76. Different Preparations of Intravenous Immunoglobulin Vary in Their Efficacy to Neutralize Streptococcal Superantigens: Implications for Treatment of Streptococcal Toxic Shock Syndrome
77. Structural and Functional Properties of Staphylococcal Superantigen-Like Protein 4
78. Intramucosal Bacterial Microcolonies Exist in Chronic Rhinosinusitis without Inducing a Local Immune Response
79. Letters to the Editor
80. Antigen Targeting to Major Histocompatibility Complex Class II with Streptococcal Mitogenic Exotoxin Z-2 M1, a Superantigen-Based Vaccine Carrier
81. Synthesis of a Dicarba Analogue of Human β-Defensin-1 Using a Combined Ring Closing Metathesis–Native Chemical Ligation Strategy
82. Synthesis and anti-Helicobacter pylori activity of analogues of spirolaxine methyl ether
83. Clarifying the Mechanism of Superantigen Toxicity
84. Interaction of Human, Rat, and Mouse Immunoglobulin A (IgA) with Staphylococcal Superantigen-like 7 (SSL7) Decoy Protein and Leukocyte IgA Receptor
85. A convergent synthesis of the [4.4]-spiroacetal-γ-lactones cephalosporolides E and F
86. Specificity of Staphylococcal Superantigen-Like Protein 10 toward the Human IgG1 Fc Domain
87. Staphylococcal Superantigen Super-Domains in Immune Evasion
88. Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy
89. The bacterial superantigen and superantigen-like proteins
90. Increased surface toll-like receptor 2 expression in superantigen shock
91. Crystal Structures of the Staphylococcal Toxin SSL5 in Complex with Sialyl Lewis X Reveal a Conserved Binding Site that Shares Common Features with Viral and Bacterial Sialic Acid Binding Proteins
92. The Cytokine Response to Streptococcal Superantigens Varies Between Individual Toxins and Between Individuals: Implications for the Pathogenesis of Group A Streptococcal Diseases
93. A Competitive Mechanism for Staphylococcal Toxin SSL7 Inhibiting the Leukocyte IgA Receptor, FcαRI, Is Revealed by SSL7 Binding at the Cα2/Cα3 Interface of IgA
94. The impact of the Research Methods Support Structure on research capacity in rural New South Wales
95. Involvement of Streptococcal Mitogenic Exotoxin Z in Streptococcal Toxic Shock Syndrome
96. Variations in the protective immune response against streptococcal superantigens in populations of different ethnicity
97. The Staphylococcal Superantigen-Like Protein 7 Binds IgA and Complement C5 and Inhibits IgA-FcαRI Binding and Serum Killing of Bacteria
98. Crystallographic and Mutational Data Show That the Streptococcal Pyrogenic Exotoxin J Can Use a Common Binding Surface for T-cell Receptor Binding and Dimerization
99. Chapter 51 - Streptococcal superantigenic toxins
100. Two Novel Superantigens Found in Both Group A and Group C Streptococcus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.